NO2470168T3 - - Google Patents

Info

Publication number
NO2470168T3
NO2470168T3 NO10747777A NO10747777A NO2470168T3 NO 2470168 T3 NO2470168 T3 NO 2470168T3 NO 10747777 A NO10747777 A NO 10747777A NO 10747777 A NO10747777 A NO 10747777A NO 2470168 T3 NO2470168 T3 NO 2470168T3
Authority
NO
Norway
Application number
NO10747777A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2470168T3 publication Critical patent/NO2470168T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO10747777A 2009-08-26 2010-08-24 NO2470168T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
NO2470168T3 true NO2470168T3 (de) 2018-06-30

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10747777A NO2470168T3 (de) 2009-08-26 2010-08-24

Country Status (17)

Country Link
US (3) US20110207828A1 (de)
EP (1) EP2470168B1 (de)
JP (2) JP5785546B2 (de)
CN (1) CN102647981B (de)
AU (1) AU2010286704B2 (de)
BR (1) BR112012004167A2 (de)
CA (1) CA2772294C (de)
DK (1) DK2470168T3 (de)
EA (1) EA028677B1 (de)
ES (1) ES2663709T3 (de)
HU (1) HUE037592T2 (de)
MX (1) MX337990B (de)
NO (1) NO2470168T3 (de)
PL (1) PL2470168T3 (de)
PT (1) PT2470168T (de)
SI (1) SI2470168T1 (de)
WO (1) WO2011025785A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
DK1888059T3 (en) * 2005-06-01 2015-03-30 Edison Pharmaceuticals Inc Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EP2220030B1 (de) 2007-11-06 2016-01-13 Edison Pharmaceuticals, Inc. 4-(p-chinonyl)-2-hydroxybutanamidderivate zur behandlung von mitochondrialen krankheiten
WO2009089224A1 (en) 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
PL2963006T3 (pl) 2008-10-28 2019-01-31 Bioelectron Technology Corporation Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie
NO2424495T3 (de) 2009-04-28 2018-06-16
EP2519232A1 (de) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Behandlung von leigh-syndrom und leigh-like-syndrom mit tocotrienolchinonen
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
EP2734512B1 (de) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Verfahren zur selektiven oxidation von alpha-tocotrienol in gegenwart von nicht-alpha-tocotrienolen
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
CN104507309B (zh) 2012-03-19 2017-05-03 奇达拉治疗公司 用于棘白菌素类化合物的给药方案
CA2883882A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (de) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroarylsubstituierte chinonderivate zur behandlung von oxidativen stresserkrankungen
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
SI3233786T1 (sl) 2014-12-16 2022-08-31 PTC Therapeutics, Inc., Polimorfne in amorfne oblike (R)-2-hidroksi-2-metil-4-(2,4,5-trimetil- 3,6-dioksocikloheksa-1,4-dienil)butanamida
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP7224916B2 (ja) 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
EP3651801A4 (de) 2017-07-12 2021-04-07 Cidara Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von pilzinfektionen
WO2020010180A1 (en) * 2018-07-03 2020-01-09 Cardio Vascular Bio Therapeutics, Inc. Compositions and methods for treating stroke
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
JP2022505257A (ja) 2018-10-17 2022-01-14 ピーティーシー セラピューティクス, インコーポレイテッド α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン
US11584728B2 (en) 2019-10-04 2023-02-21 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US20210162003A1 (en) * 2019-10-17 2021-06-03 The Penn State Research Foundation Regenerating functional neurons for treatment of hemorrhagic stroke
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
JP2024525232A (ja) 2021-07-08 2024-07-10 ピーティーシー セラピューティクス、インコーポレイテッド 2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを含む医薬組成物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素qを主成分とする脳循環障害治療剤
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
ID26335A (id) 1997-11-17 2000-12-14 Lipogenic Inc Metoda untuk mencegah restenosis dengan menggunakan tokotrienol
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US20020132845A1 (en) * 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
WO2003015494A2 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7491312B2 (en) * 2002-10-30 2009-02-17 Edison Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7514461B2 (en) * 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
DK1888059T3 (en) * 2005-06-01 2015-03-30 Edison Pharmaceuticals Inc Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
DK1933821T3 (da) * 2005-09-15 2020-10-26 Ptc Therapeutics Inc Halevarianter af redox-aktive terapeutika til behandling af mitokondriesygdomme og andre tilstande og modulation af energibiomarkører
EA019675B1 (ru) * 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
CA2674368A1 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EP2220030B1 (de) * 2007-11-06 2016-01-13 Edison Pharmaceuticals, Inc. 4-(p-chinonyl)-2-hydroxybutanamidderivate zur behandlung von mitochondrialen krankheiten
US20100266591A1 (en) * 2008-01-07 2010-10-21 Peter Bugelski Method of treating erythropoietin hyporesponsive anemias
WO2009089224A1 (en) * 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2262519A4 (de) * 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc Behandlung von gehör- und gleichgewichtsstörungen mit redoxaktiven therapeutika
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
EP2303309A2 (de) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Behandlung von mitochondrialen erkrankungen mit einem erythropoetin-mimetikum
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) * 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) * 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
US8314153B2 (en) * 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) * 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
PL2963006T3 (pl) * 2008-10-28 2019-01-31 Bioelectron Technology Corporation Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie
CA2760357A1 (en) * 2009-04-28 2010-11-04 Ampere Life Sciences, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
CA2759984A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
NO2424495T3 (de) * 2009-04-28 2018-06-16
MX2011013558A (es) * 2009-06-25 2012-04-30 Ampere Life Sciences Inc Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos.
EP2519232A1 (de) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Behandlung von leigh-syndrom und leigh-like-syndrom mit tocotrienolchinonen
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) * 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20120295985A1 (en) * 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control

Also Published As

Publication number Publication date
DK2470168T3 (en) 2018-05-07
US20110207828A1 (en) 2011-08-25
JP2015091899A (ja) 2015-05-14
CN102647981A (zh) 2012-08-22
US20170007553A1 (en) 2017-01-12
EP2470168B1 (de) 2018-01-31
US20180344667A1 (en) 2018-12-06
CA2772294A1 (en) 2011-03-03
CN102647981B (zh) 2016-09-28
PT2470168T (pt) 2018-03-28
BR112012004167A2 (pt) 2016-03-29
MX2012002374A (es) 2012-04-10
MX337990B (es) 2016-03-30
ES2663709T3 (es) 2018-04-16
SI2470168T1 (en) 2018-05-31
AU2010286704B2 (en) 2016-10-20
JP5785546B2 (ja) 2015-09-30
EA201200355A1 (ru) 2012-07-30
HUE037592T2 (hu) 2018-09-28
PL2470168T3 (pl) 2018-06-29
EA028677B1 (ru) 2017-12-29
AU2010286704A1 (en) 2012-03-22
CA2772294C (en) 2018-08-21
WO2011025785A1 (en) 2011-03-03
EP2470168A1 (de) 2012-07-04
JP2013503168A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
BR112012012396A2 (de)
BR112012008267A2 (de)
BR112012008195A2 (de)
BR112012000607A2 (de)
BRPI0925311A2 (de)
BR112012012487A2 (de)
BR112012000665A2 (de)
NO2470168T3 (de)
BR112012003853A2 (de)
BR112012009797A2 (de)
BR112012012080A2 (de)
BR112012009446A2 (de)
BR112012009703A2 (de)
BR112012010357A2 (de)
BR112012007656A2 (de)
BR112012002627A2 (de)
BR112012001263A2 (de)
BR112012000159A2 (de)
BR112012007654A2 (de)
BR112012007672A2 (de)
BR112012005951A2 (de)
BR112012000255A2 (de)
BR112012009404A2 (de)
BR112012000156A2 (de)
BRPI0924617A2 (de)